In the current study, we found that anti-ANGPTL3/IL22 could effectively reduce the production of inflammatory factors including IL-6, TNF-α and IL-1β by inhibiting NF-κB p65/NLRP3 inflammasome, suggesting that the beneficial effect of anti-ANGPTL3/IL22 in the treatment of DN may be attributed to the attenuation of the inflammatory response. This evidence concerns the gene IL1B and liver dysplastic nodule.